NewEdge Advisors’s Pliant Therapeutics PLRX Stock Holding History

NewEdge Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35	Closed	-$677	–	3953
2022 Q4	$677	Buy	+35	New	+$732	﹤0.01%	3124

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NewEdge Advisors's PLRX Position: Q1 2023 in Review

NewEdge Advisors sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 35 shares — an estimated $677 sold.

NewEdge Advisors first reported a position in PLRX in Q4 2022 and held it in 1 quarter. The position peaked at $677 in Q4 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

NewEdge Advisors reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 35 Pliant Therapeutics shares in Q1 2023, an estimated $677.
NewEdge Advisors first reported a position in Pliant Therapeutics in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Pliant Therapeutics position peaked at $677 in Q4 2022.
143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.